EUVIMEDOpdag EUVIMED
Crossref

CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin

Jackson K B Cahn iD, Henry Ludwicki, Jillian Shingler, Shannon Gulvin, Young Zhang, Adam Kristopeit, Christopher Ton, Michael A Winters, James M Wagner, Jeffrey Moore iD

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.29028 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2025. Written by Jackson K B Cahn and 9 co-authors. Institution: Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA. Major MEDLINE topics: Gene Editing, Fibronectins, CRISPR-Cas Systems, Viral Vaccines. Cited 2 times so far (Crossref); 31 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Removal of host cell components is a significant cost driver in the production of live virus vaccines. Filtration processes such as tangential flow filtration can be effective in this capacity by leveraging the relative size difference between viral particles and host proteins; however, filtration membranes can be fouled by larger proteins, particularly those of the extracellular matrix. In this study, we used CRISPR editing to insert the recognition element of the highly‐selective TEV protease into various positions of the gene encoding fibronectin in the genome of the Vero cell line, a common platform for viral production. By screening edited cell lines, we identified a promising candidate line in which fibronectin could be effectively removed by treating with the protease during processing, eliminating filter fouling and allowing for viral purification without the need for costly chromatography steps.

Subjects

MeSH terms (MEDLINE)

Gene EditingFibronectinsCRISPR-Cas SystemsViral VaccinesAnimalsChlorocebus aethiopsVero CellsProteolysisVaccines, Attenuated

Author keywords

CRISPR editingfibronectinlive‐virus vaccinesprotein removalultrafiltrationvirus purification

Substances

FibronectinsViral VaccinesVaccines, Attenuated

Authors and institutions

  • Process Research & Development, Merck & Co. Inc., Rahway, New Jersey, USA.
  • Process Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.
  • Analytical Research & Development, Merck & Co. Inc., West Point, Pennsylvania, USA.

ORCID profiles: Jackson K B Cahn, Jeffrey Moore

Cite

APA

Cahn, J. K. B., Ludwicki, H., Shingler, J., Gulvin, S., Zhang, Y., Kristopeit, A., Ton, C., Winters, M. A., Wagner, J. M., & Moore, J. (2025). CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.29028

Vancouver

Cahn JKB, Ludwicki H, Shingler J, Gulvin S, Zhang Y, Kristopeit A, et al. CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.29028

BibTeX
@article{Cahn2025,
  author = {Cahn, Jackson K B and Ludwicki, Henry and Shingler, Jillian and Gulvin, Shannon and Zhang, Young and Kristopeit, Adam and Ton, Christopher and Winters, Michael A and Wagner, James M and Moore, Jeffrey},
  title = {CRISPR‐Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.29028}
}
Start for free →